Genzyme, a Sanofi Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Genzyme, a Sanofi Company sits in the top decile of US sponsors by registered trial count (#154 of 15,742 sponsors by registered trial count).
Genzyme, a Sanofi Company: 196 sponsored US clinical trials, 4 recruiting.
Genzyme, a Sanofi Company sponsors 196 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 159 completed. 65 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glycogen Storage Disease Type II (GSD-II), with 5 trials.
Top-decile sponsor footprint
Genzyme, a Sanofi Company ranks in the top decile of sponsors by registered trial count (#154 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
159 of 188 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
196 total, page 2 of 4
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
NCT01526785
A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects
NCT01452542
A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent
NCT01579149
A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults
NCT01357811
Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa
NCT01288027
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
NCT01164475
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
NCT01074944
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
NCT01024998
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00990054
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)
NCT00891202
A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)
NCT00991133
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
NCT00701129
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
NCT00943111
An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
NCT00930553
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
NCT00942799
Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis
NCT00853242
Immune Tolerance Induction Study
NCT00701701
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
NCT00701415
A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)
NCT00750334
Growth and Development Study of Alglucosidase Alfa
NCT00486889
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00694590
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
NCT00601107
Sepraspray™ Laparoscopic Myomectomy Study
NCT00624390
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
NCT00548405
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
NCT00530348
Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter
NCT00454220
A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)
NCT00531232
A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)
NCT00444626
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
NCT00464321
High Dose or High Dose Frequency Study of Alglucosidase Alfa
NCT00483379
A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection
NCT00463021
A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea
NCT00466635
Late-Onset Treatment Study Extension Protocol
NCT00455195
A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
NCT00454116
A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis
NCT00454350
A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs)
NCT00417469
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
NCT00418886
Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)
NCT00410566
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
NCT00410761
A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis
NCT00418600
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
NCT00404924
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
NCT00373529
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
NCT00356460
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
NCT00317642
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
NCT00364351
A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
NCT00358956
A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients
NCT00358150
Study of the Effects of Fabrazyme Treatment on Lactation and Infants
NCT00230607
ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
NCT00312377
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
NCT00328198
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 66 |
| Phase 3 | 40 |
| Phase 4 | 25 |
Therapeutic Areas
What is open in the Genzyme, a Sanofi Company pipeline
4 recruiting of 196 indexed (2% open); 159 completed (81%).
Phase mix: 65 late (III/IV) vs 114 early (I/II) (early-phase heavy).
Top condition: Glycogen Storage Disease Type II (GSD-II) (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Genzyme, a Sanofi Company: open-pipeline peers nationwide
Peers matched on 196 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Genzyme, a Sanofi Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 196 trials (± recruiting share)
- Hospital for Special Surgery, New York · 194 trials · 18% recruiting
- Vertex Pharmaceuticals Incorporated · 191 trials · 10% recruiting
- National Center for Complementary and Integrative Health (NCCIH) · 203 trials · 3% recruiting
- The University of Texas Medical Branch, Galveston · 203 trials · 14% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Cynosure · 2% recruiting · 49 trials
- Carelon Research · 2% recruiting · 50 trials
- Sun Pharmaceutical Industries · 2% recruiting · 48 trials
- Sanofi Pasteur, a Sanofi Company · 2% recruiting · 153 trials
Related
What to do with this Genzyme, a Sanofi Company page
196 registered trials is a research-attention snapshot, not an endorsement of Genzyme, a Sanofi Company or any single study.
- 4 of Genzyme, a Sanofi Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Glycogen Storage Disease Type II (GSD-II) is the condition Genzyme, a Sanofi Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glycogen Storage Disease Type II (GSD-II) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Genzyme, a Sanofi Company pipeline card: 196 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.